Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that additional data from the Phase 3 VELOUR trial will be presented at the 2011 European Multidisciplinary Cancer Congress (EMCC) which will take place from September 23-27 in Stockholm, Sweden.
The data will be presented as a late breaker, by Prof. Josep Tabernero, on Sunday, September 25, at 6:40 AM EDT. Prof. Tabernero is Head of Medical Oncology at Vall d'Hebron University Hospital, Spain, and one of the lead investigators in the VELOUR trial. The title of his presentation is "Results from VELOUR, a Phase 3 Study of Aflibercept Versus Placebo in Combination with FOLFIRI for the Treatment of Patients with Previously Treated Metastatic Colorectal Cancer: Results from Prespecified Subgroup Analyses."
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapy